Published • loading... • Updated
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
The phase 2b COPERNICUS study found fewer than 1% of patients stopped treatment because of side effects at one year, Johnson & Johnson said.
- On Monday, Johnson & Johnson announced new Phase 2b COPERNICUS study findings evaluating RYBREVANT FASPRO plus LAZCLUZE with prophylactic strategies in patients with previously untreated advanced EGFR-mutated NSCLC.
- COPERNICUS uses a pragmatic design reflecting everyday clinical practice, enrolling a racially and ethnically diverse patient population across academic and community sites while testing less frequent dosing and enhanced dermatologic prophylaxis.
- Rash, administration-related reactions, and venous thromboembolism occurred in 25 percent, three percent, and three percent of patients, respectively; these rates were lower than the 55 percent, 55 percent, and 23 percent observed during the first four months of the MARIPOSA study.
- "These latest results mark an important evolution in the treatment approach," said Balazs Halmos, Director of Thoracic Oncology at Montefiore Einstein Comprehensive Cancer Center.
- These findings strengthen evidence for the regimen as a first-line treatment and reflect Johnson & Johnson's continued focus on improving how cancer therapies are delivered and managed in everyday clinical settings.
Insights by Ground AI
45 Articles
45 Articles
LoudounTimes.com+44 Reposted by 44 other sources
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxisFewer than 1% of patients discontinued treatment due to treatment-related events at one yearNew findings from Johnson & Johnson build on the MARIPOSA survival benefit…
Coverage Details
Total News Sources45
Leaning Left7Leaning Right5Center26Last UpdatedBias Distribution68% Center
Bias Distribution
- 68% of the sources are Center
68% Center
L 19%
C 68%
13%
Factuality
To view factuality data please Upgrade to Premium
